TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading

Lippman (EVP, Business Development) sold 41,658 shares at $35.58 via scheduled 10b5-1 plan; post-sale holdings 44,191 shares.

Evan Lippman executed 2 separate sales totaling 41,658 shares for $1,482,366.60 at $35.58 per share on 2026-05-14, reducing his post-transaction holdings to 44,191 shares from 85,849 shares (a -48.5% reduction in position size). This transaction was pre-arranged under a 10b5-1 trading plan adopted on 2025-11-10, making it a scheduled, non-discretionary sale that cannot be interpreted as reflecting real-time market judgment or conviction signals. At the transaction price of $35.58, Lippman sold near TEVA's 52-week high of $37.34, though the current price of $34.05 reflects a subsequent -8.8% decline from that high. The sale is material in absolute dollar terms ($1.5M) and represents a substantial reduction of his equity position, but the pre-arranged nature constrains inference about signaling or forward-looking intent.

CFO (then) Kalif Eliyahu Sharon sold 153,251 shares of TEVA at $35.61 under 10b5-1 plan; stock now -8.8% from 52-week high.

Kalif Eliyahu Sharon, who was CFO at the time of this transaction, executed a scheduled sale of 153,251 shares ($5.5M value) under a pre-arranged 10b5-1 trading plan adopted on 2025-11-26, reducing his holdings by 47.1%. The sale occurred at $35.61 on 2026-05-14; the stock currently trades at $34.05, down 8.8% from its 52-week high of $37.34. His prior four trades at TEVA show subsequent 90-day returns of +1.9%, +14.6%, +8.2%, and +23.0%, while his cross-ticker track record of 4 prior sells averaged 90-day return of +11.9%. Because this transaction is part of a scheduled 10b5-1 plan, it reflects commitment to a predetermined schedule rather than discretionary market timing decisions. Investors should note that Sharon is no longer the current CFO per the most recent 10-Q/10-K SOX certification.

Daniell Richard, EVP Europe Commercial at TEVA, sells 30,000 shares (35% of holdings) as stock nears 52-week highs.

Daniell Richard, EVP Europe Commercial, sold a substantial block representing more than one-third of his holdings at a time when TEVA's stock is trading near its 52-week highs. His prior selling activity over the past two months shows consistent patterns — in the 30-day windows following his earlier March sales, the stock declined, indicating well-timed exits that avoided further downside. However, over longer 90-day periods, those earlier sales preceded modest gains, suggesting his timing works on near-term windows but not intermediate horizons. The company itself remains solidly profitable with healthy revenue and earnings, so this sale does not signal financial distress; rather, it reflects a seasoned executive taking liquidity at a strong price point. This sale marks the continuation of a disciplined selling pattern rather than a sudden shift in conviction.

Officer Sabag Mark sells 144,180 TEVA shares (64% of holdings) for $5M; sixth open-market sale in 36 months with mixed timing history.

Mark Sabag, a TEVA officer, executed his sixth open-market sale in the past three years, disposing of roughly two-thirds of his remaining stake for over $5 million. His prior five sales at TEVA showed mixed results: two were well-timed exits where the stock subsequently declined, while three were followed by meaningful gains, suggesting he has historically exited at suboptimal moments more often than not. TEVA itself remains a profitable company with growing revenue and solid quarterly results, but the stock has rallied sharply in recent weeks and now trades near its 52-week high—a position where executives historically take profits more readily. Sabag's sustained pattern of selling, combined with the price level at which this sale occurred, reflects opportunistic liquidation rather than distress or major operational concern, but the repeated exits over three years underscore a pattern of persistent reduction in his personal exposure to the company.